UC Riverside Reproductive Hazard Questionnaire

Appendix A

**The purpose of this voluntary questionnaire is to help identify:**

* **If any chemical, biological, or radiological reproductive hazards are present in your work area**
* **The extent of any potential exposures**
* **Control methods to prevent or minimize exposure**
* **Information and training.**

**EH&S will conduct a site hazard assessment of your work area with you to assist in the completion of this Reproductive Hazard Questionnaire.**

**Return the completed (employee portion) questionnaire to EH&S:**

**E-mail:** [**ehsocchealth@ucr.edu**](mailto:ehsocchealth@ucr.edu)

**OR**

**Mail: Environmental Health & Safety**

**900 University Ave.**

**Riverside, CA 92521**

**951-827-5528**

**Declaration of Pregnancy and Reproductive Health Consultation**

Laboratory workers often face potential hazards that can have adverse effects on reproduction. Given that the reproductive effects of most chemicals are still not fully evaluated, it is crucial for laboratory workers who are pregnant, nursing, or planning to conceive (both men and women) to consider seeking guidance from UCR Environmental Health and Safety (EH&S). It is entirely voluntary to report your condition to EH&S. EH&S can assist in assessing workplace reproductive hazards and provide recommendations for control measures to minimize exposure. Additionally, laboratory personnel who inform EH&S are encouraged to discuss all workplace hazards with their healthcare provider and, in certain cases, may consider consulting with an Occupational Medicine doctor. Ultimately, the decision to continue working in the laboratory while pregnant or planning to conceive, considering associated risks, rests with the individual lab worker/student.

**Individual Responsibility:**

* Ensuring a safe laboratory environment depends on each individual's commitment to safety during research activities.
* Openly discussing workplace hazards with their healthcare provider.
* Carefully evaluate and decide whether to accept the risks associated with working in the laboratory while pregnant or planning to conceive.

**Confidentiality:** Inquiries related to pregnancy are treated with strict confidentiality. Therefore, you can consult the occupational health team without notifying your department or PI. If necessary, an impromptu assessment of the laboratory can be conducted without informing other lab members. However, if accommodations are required for the safety of the unborn child, your supervisor may need to be informed.

**Reproductive hazards** encompass substances or agents that can affect the reproductive health of women or men, or their ability to have healthy children. These hazards may be chemical, biological, radiological, or physical in nature, and exposure can occur through ingestion, injection, inhalation, or absorption. Possible health effects include infertility, miscarriage, birth defects, and developmental issues in children. The extent to which a person may be affected depends on various factors, including the type of hazard, method of exposure, duration of exposure, dose received, and individual variation (e.g., age and pregnancy stage at the time of exposure).

I, \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ [your name], voluntarily declare my pregnancy to the University of California, Riverside on \_\_\_\_\_\_\_\_\_\_\_ [Date]. I understand that I will be working in a laboratory setting at UCR that contains chemicals, biologicals, and radioactive materials known to the state of California to cause cancer or reproductive toxicity. You can access the chemical list at <https://oehha.ca.gov/proposition-65/proposition-65-list>.

I am aware that exposing a pregnant female to excessive amounts of chemicals listed as teratogens may cause harm to the developing embryo or fetus. Teratogenic chemicals fall under the broader category of chemicals marked with an "R" in the special information section on chemical warning labels and Safety Data Sheets.

I understand that UCR encourages me to provide a list of chemicals/any hazards used to my healthcare provider to make informed decisions during my pregnancy while working with chemicals, biologicals, or radioactive materials.

**Note: I reserve the right to revoke this declaration at any time without providing an explanation by submitting a signed and dated statement requesting the revocation.**

Print Name: [Your Name] \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature: [Your Signature] \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: [Date]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_



**Pregnancy Consultation Form**

I, \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ [declared pregnant woman] reviewed that the risks associated with working with chemicals, biological materials, and/or radioactive materials through the Reproductive Hazards and the Reproductive Health program.

If working with radiation during pregnancy, the declared pregnant woman has received a complete copy of the U.S. Nuclear Regulatory Commission Regulatory Guide 8.13 and has been given the option to participate in a monitoring program for pregnant workers.

I would like to proceed with a consultation with an Occupational Health Physician. Please provide your Birthdate so Occupational Health can generate a clinic referral. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Declared Pregnant Woman (signature): Click or tap here to enter text. Date: Click or tap here to enter text.

Estimated Conception Date: Click or tap here to enter text. Estimated Delivery Date: Click or tap here to enter text.

EH&S Representative or Radiation Safety Officer (signature): Click or tap here to enter text.

**Appendix A: Reproductive Hazard Questionnaire**

|  |  |  |
| --- | --- | --- |
| Date Click or tap here to enter text. | Name Click or tap here to enter text. | UCR ID# Click or tap here to enter text. |
| Dept. Click or tap here to enter text. | Phone Click or tap here to enter text. | E-mail Click or tap here to enter text. |
| Supervisor Click or tap here to enter text. | Phone Click or tap here to enter text. | E-mail Click or tap here to enter text. |
| Laboratory Location: Click or tap here to enter text. | | |

1. Agents and physical hazards encountered at work – Continue on a separate page if needed.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| List Agents and Hazards currently using or expect to use during a pre-conception or pregnancy period. | Frequency and Duration of use (once/day for two hours, etc.) | Physical State of Agents (solid, liquid, gas) | The quantity used per each use, in units of time (e.g., 10  ml per week) | Personal Protective Equipment used (gloves, respirator, etc.) | Engineering & Administrative Controls used or planned to use (fume hood, BSC, radiation barrier, job rotation, etc.) | Tasks – Describe how the material will be used. |
| **Chemical Agents:** | | | | | | |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| **Biological Agents (and Biosafety level):** | | | | | | |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| **Radiation:** | | | | | | |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| **Physical Hazards:** | | | | | | |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |

1. Questions about chemicals:
   1. Do other people in your area use the same chemicals? Click or tap here to enter text.If yes, how many other people?Click or tap here to enter text.
   2. Are any of these chemicals heated?Click or tap here to enter text. If yes, to what temperature? Click or tap here to enter text.Which ones?Click or tap here to enter text.

Click or tap here to enter text.

* 1. Can you smell or taste any chemical fumes or vapors where you work? Click or tap here to enter text.If yes, which ones?Click or tap here to enter text.
  2. Do you feel sick when you work with any of the chemicals and feel better at other times?Click or tap here to enter text.
  3. Do any of the chemicals you work with get on your skin?Click or tap here to enter text. If yes, which ones?Click or tap here to enter text.

1. Do you have any specific health or safety concerns about your work? If so, describe:Click or tap here to enter text.

Click or tap here to enter text.

1. Have you disclosed your pregnancy or intent to conceive to your direct supervisor or, in cases of a laboratory course, your faculty/professor/T.A.

Yes  No

1. Have you shared any information about the type of work or research you conduct with your treating physician? Primary Care?

Yes  No

If yes, do you have medical restrictions? And please provide a copy. What are those restrictions?

Click or tap here to enter text.

1. Do you work in the vivarium with live animals or animal tissues?

Yes  No

If Yes, have you updated your Animal Handler’s and User’s Medical questionnaire? If you have not, this would be an appropriate time to update

Yes  No

1. Do you store or consume food or beverages in your workplace?

Yes  No

1. What type of personal protective equipment do you wear while working?

|  |  |  |  |
| --- | --- | --- | --- |
| **Eye/Face Protection** | **Foot Protection** | | **Head Protection** |
| **Safety glasses with side shields**  **Laser safety glasses**  **Safety goggles**  **Face shield**  **Welder’s helmet/ face shield** | **Safety shoes/boots**  **Toe caps**  **Metatarsal guards**  **Rubber boots** | | **Hard hat**  **Hearing protection –**  **earplugs, earmuffs** |
| **Body Protection** | **Hand Protection/Gloves** | | |
| **Fall restraint/fall protection**  **Rubber apron**  **Disposable Tyvek lab coat/coveralls**  **A lab coat or coveralls**  **Welding leather sleeve guards**  **Nomex Coveralls**  **Other**: Click or tap here to enter text. | **Leather**  **Natural rubber**  **Cotton (coated/not coated)**  **Nitrile**  **Heat-resistant**  **Neoprene**  **Chemical resistant**  **Butyl rubber**  **Latex**  **Other (PVC, PVA, Viton)**  **Cryogenic**  **Anti-vibration**  **Cut resistant (e.g., Kevlar)**  **Other:** Click or tap here to enter text. | | |
| **Respiratory Protection** | | | |
| **Filtering Facepiece respirator (N, P, or R)**  **Air-purifying respirator**  **Supplied airline**  **Half facepiece**  **Self-contained breathing apparatus (SCBA)**  **Full facepiece**  **Escape-only air pack**  **PAPR unit** | | **APR Chemical Cartridge/Filter Types:**  **Multi-gas/OV**  **AG/Acid Gas**  **OV/Organic Vapor**  **OV/AG**  **P-100**  **Ammonia** | |

1. Have you had any spills or unintentional exposures recently? Click or tap here to enter text.

If so, describe: Click or tap here to enter text.

1. Describe your work environment: Click or tap here to enter text.
2. If in a laboratory environment, how much of your time do you spend doing:
   1. Work on a bench Click or tap here to enter text. %
   2. Work in a fume hood Click or tap here to enter text.%
3. Office work Click or tap here to enter text.%
4. Other Click or tap here to enter text.%
5. Are other people working in the same room as you? Yes  No
6. Describe the physical demands of your work:

|  |  |  |
| --- | --- | --- |
|  | **Duration & Frequency** | **Description** |
| **Lifting** | Click or tap here to enter text. | Click or tap here to enter text. |
| **Bending/Twisting** | Click or tap here to enter text. | Click or tap here to enter text. |
| **Sitting** | Click or tap here to enter text. | Click or tap here to enter text. |
| **Standing** | Click or tap here to enter text. | Click or tap here to enter text. |

|  |  |  |
| --- | --- | --- |
| \_Click or tap here to enter text. | Click or tap here to enter text. |  |
| **Person Completing Form** | **Signature** | **Date** |

**EH&S to Complete Below Line**

Exposure Control Recommendations:

|  |
| --- |
| Engineering Controls**:**Click or tap here to enter text. |
| Administrative Controls**:**Click or tap here to enter text. |
| Personal Protective Equipment:Click or tap here to enter text. |

|  |  |  |
| --- | --- | --- |
| \_Click or tap here to enter text. | Click or tap here to enter text. | Click or tap here to enter text. |
| **EH&S Personnel Name** | **Signature** | **Date** |
| \_Click or tap here to enter text.  **EH&S Title** |  |  |

**Appendix B:**

**List of Chemicals that are Potential Reproductive Health Hazards**

## Please note that this list may not be exhaustive and that Safety Data Sheets of specific chemicals should be reviewed to ensure they are not a reproductive hazard*.*

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 50-02-2 | Dexamethasone |
| 50-03-3 | Hydrocortisone 21-acetate |
| 50-28-2 | Estradiol |
| 50-32-8 | benzo[a]pyrene; benzo[def]chrysene |
| 50-35-1 | Thalidomide |
| 50-50-0 | Estradiol benzoate |
| 50-76-0 | Dactinomycin |
| 52-86-8 | Haloperidol |
| 53-16-7 | Estrone |
| 53-21-4 | Cocaine hydrochloride |
| 56-75-7 | Chloramphenicol |
| 57-63-6 | Ethinylestradiol |
| 57-85-2 | Testosterone propionate |
| 58-22-0 | Testosterone |
| 59-14-3 | 5-Bromo-2ʹ-deoxyuridine; BrdU |
| 59-92-7 | Levodopa |
| 60-54-8 | Tetracycline |
| 60-56-0 | Methiamazole |
| 61-82-5 | amitrole (ISO); 1,2,4-triazol-3-ylamine |
| 62-56-6 | thiourea; thiocarbamide |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 66-81-9 | cycloheximide (ISO); 4-{}{(2R)-2-  [(1S,3S,5S)-3,5-dimethyl-2-  oxocyclohexyl]-2- hydroxyethyl}}piperidine-2,6-dione |
| 67-66-3 | chloroform; trichloromethane |
| 68-12-2 | N,N-dimethylformamide; dimethyl formamide |
| 71-48-7 | cobalt di(acetate) |
| 75-12-7 | formamide |
| 75-15-0 | carbon disulphide |
| 75-26-3 | 2-bromopropane |
| 76-25-5 | 9-α-fluoro-11-β,21-dihydroxy-16-α,17-α- isopropylidenedioxypregna-1,4-diene- 3,20-dione; Triamcinolone acetonide |
| 76-43-7 | Fluoxymesterone |
| 76-74-4 | Pentobarbital |
| 76-87-9 | fentin hydroxide (ISO); triphenyltin hydroxide |
| 77-09-8 | phenolphthalein |
| 79-06-1 | acrylamide; prop-2-enamide |
| 79-07-2 | 2-chloracetamide |
| 79-16-3 | N-methylacetamide |
| 80-05-7 | bisphenol A; 4,4’- isopropylidenediphenol |
| 81-81-2 | warfarin (ISO) |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 84-17-3 | Dienesterol |
| 84-61-7 | dicyclohexyl phthalate |
| 84-69-5 | diisobutyl phthalate |
| 84-74-2 | dibutyl phthalate; DBP |
| 84-75-3 | dihexyl phthalate |
| 85-68-7 | BBP; benzyl butyl phthalate |
| 88-72-2 | 2-nitrotoluene |
| 88-85-7 | dinoseb (ISO); 6-sec-butyl-2,4- dinitrophenol |
| 95-80-7 | 4-methyl-m-phenylenediamine; 2,4- toluenediamine |
| 96-12-8 | 1,2-dibromo-3-chloropropane |
| 96-13-9 | 2,3-dibromopropan-1-ol; 2,3-dibromo-1- propanol |
| 96-18-4 | 1,2,3-trichloropropane |
| 96-24-2 | 3-chloropropane-1,2-diol; 3- Monochloro-1,2-propanediol |
| 96-45-7 | ethylene thiourea; imidazolidine-2- thione; 2-imidazoline-2-thiol |
| 97-99-4 | tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol |
| 98-54-4 | 4-tert-butylphenol |
| 98-73-7 | 4-tert-butylbenzoic acid |
| 98-95-3 | nitrobenzene |
| 100-42-5 | styrene |
| 101-80-4 | 4,4'-oxydianiline and its salts; p- aminophenyl ether |
| 102-06-7 | 1,3-diphenylguanidine |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 103-72-0 | phenyl isothiocyanate |
| 106-92-3 | allyl glycidyl ether; allyl 2,3-epoxypropyl ether; prop-2-en-1-yl 2,3-epoxypropyl ether |
| 106-94-5 | 1-bromopropane; n-propyl bromide |
| 108-88-3 | toluene |
| 108-91-8 | cyclohexylamine |
| 108-98-5 | thiophenol; benzenethiol |
| 109-75-1 | allyl cyanide |
| 109-86-4 | 2-methoxyethanol; ethylene glycol monomethyl ether |
| 110-49-6 | 2-methoxyethyl acetate; methylglycol acetate |
| 110-54-3 | n-hexane |
| 110-71-4 | 1,2-dimethoxyethane; ethylene glycol dimethyl ether; EGDME |
| 110-80-5 | 2-ethoxyethanol; ethylene glycol monoethyl ether |
| 110-85-0 | piperazine |
| 110-88-3 | 1,3,5-trioxan; trioxymethylene |
| 111-15-9 | 2-ethoxyethyl acetate; ethylglycol acetate |
| 111-41-1 | 2-(2-aminoethylamino)ethanol; (AEEA) |
| 111-77-3 | 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether |
| 111-96-6 | bis(2-methoxyethyl) ether |
| 112-49-2 | 1,2-bis(2-methoxyethoxy)ethane; TEGDME; triethylene glycol dimethyl ether; triglyme |
| 115-96-8 | tris(2-chloroethyl)phosphate |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 117-81-7 | bis(2-ethylhexyl) phthalate; di-(2- ethylhexyl) phthalate; DEHP |
| 117-82-8 | bis(2-methoxyethyl) phthalate |
| 121-14-2 | 2,4-dinitrotoluene |
| 123-39-7 | N-methylformamide |
| 127-07-1 | Hydroxyurea |
| 127-19-5 | N,N-dimethylacetamide |
| 131-18-0 | di-n-pentyl phthalate |
| 142-64-3 | piperazine dihydrochloride |
| 145-13-1 | Pregnenolone |
| 147-94-4 | Cytarabine |
| 148-82-3 | Melphalan |
| 149-57-5 | 2-ethylhexanoic acid |
| 288-32-4 | imidazole |
| 288-88-0 | 1,2,4-triazole |
| 301-04-2 | lead di(acetate) |
| 302-79-4 | Tretinoin |
| 302-97-6 | 3-oxoandrost-4-ene-17-ß-carboxylic acid |
| 309-43-3 | Secobarbital sodium |
| 330-55-2 | linuron (ISO); 3-(3,4-dichlorophenyl)-1- methoxy-1-methylurea |
| 331-39-5 | Caffeic acid |
| 335-67-1 | perfluorooctanoic acid |
| 363-24-6 | Dinoprostone; Prostaglandin E2 |
| 373-02-4 | nickel di(acetate) |
| 375-95-1 | perfluorononan-1-oic acid |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 379-79-3 | Ergotamine tartrate |
| 485-31-4 | binapacryl (ISO); 2-sec-butyl-4,6- dinitrophenyl-3-methylcrotonate |
| 510-65-4 | 19-Hydroxyandrost-4-ene-3,17-dione |
| 513-79-1 | cobalt carbonate |
| 531-76-0 | Merphalan |
| 553-71-9 | nickel dibenzoate |
| 556-52-5 | 2,3-epoxypropan-1-ol; glycidol; oxiranemethanol |
| 556-67-2 | octamethylcyclotetrasiloxane |
| 569-64-2 | malachite green hydrochloride |
| 573-58-0 | disodium 3,3'-[[1,1'-biphenyl]-4,4'- diylbis(azo)]bis(4-aminonaphthalene-1- sulphonate); C.I. Direct Red 28 |
| 591-78-6 | hexan-2-one; methyl butyl ketone; butyl methyl ketone; methyl-n-butyl ketone |
| 592-62-1 | methyl-ONN-azoxymethyl acetate; methyl azoxy methyl acetate |
| 595-33-5 | Megestrol acetate |
| 602-01-7 | 2,3-dinitrotoluene |
| 605-50-5 | diisopentylphthalate |
| 606-20-2 | 2,6-dinitrotoluene |
| 610-39-9 | 3,4-dinitrotoluene |
| 618-85-9 | 3,5-dinitrotoluene |
| 619-15-8 | 2,5-dinitrotoluene |
| 624-83-9 | methyl isocyanate |
| 625-45-6 | methoxyacetic acid |
| 629-14-1 | 1,2-diethoxyethane |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 630-08-0 | carbon monoxide |
| 683-18-1 | dibutyltin dichloride; (DBTC) |
| 753-73-1 | dimethyltin dichloride |
| 846-49-1 | Lorazepam |
| 872-50-4 | N-methyl-2-pyrrolidone; 1-methyl-2- pyrrolidone |
| 900-95-8 | fentin acetate (ISO); triphenyltin acetate |
| 993-16-8 | trichloromethylstannane |
| 1303-00-0 | gallium arsenide |
| 1303-86-2 | diboron trioxide; boric oxide |
| 1303-96-4 | disodium tetraborate decahydrate; borax decahydrate |
| 1306-19-0 | cadmium oxide (non-pyrophoric) |
| 1306-23-6 | cadmium sulfide |
| 1314-62-1 | divanadium pentaoxide; vanadium pentoxide |
| 1330-43-4 | disodium tetraborate, anhydrous; boric acid, disodium salt |
| 1333-82-0 | chromium (VI) trioxide |
| 1335-32-6 | lead acetate, basic |
| 1344-37-2 | lead sulfochromate yellow; C.I. Pigment Yellow 34; [This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77603.] |
| 1420-07-1 | dinoterb (ISO); 2-tert-butyl-4,6- dinitrophenol |
| 1589-47-5 | 2-methoxypropanol |
| 1593-77-7 | dodemorph (ISO); 4-cyclododecyl-2,6- dimethylmorpholine |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 1671-49-4 | 4-mesyl-2-nitrotoluene |
| 1689-83-4 | ioxynil (ISO); 4-hydroxy-3,5- diiodobenzonitrile |
| 1689-84-5 | bromoxynil (ISO); 3,5-dibromo-4- hydroxybenzonitrile; bromoxynil phenol |
| 1689-99-2 | bromoxynil octanoate (ISO); 2,6- dibromo-4-cyanophenyl octanoate |
| 1763-23-1 | perfluorooctane sulfonic acid; heptadecafluorooctane-1-sulfonic acid |
| 1836-75-5 | nitrofen (ISO); 2,4-dichlorophenyl 4- nitrophenyl ether |
| 1937-37-7 | disodium 4-amino-3-[[4'-[(2,4- diaminophenyl)azo][1,1'-biphenyl]-4- yl]azo]-5-hydroxy-6- (phenylazo)naphtalene-2,7- disulphonate; C.I. Direct Black 38 |
| 1951-97-9 | piperazine phosphate |
| 2022-85-7 | Flucytosine |
| 2040-90-  6 | 2-chloro-6-fluoro-phenol |
| 2068-78-2 | Vincristine sulfate |
| 2079-89-2 | Bis(3-aminopropiononitrile) fumarate, BAPN |
| 2122-19-2 | propylenethiourea |
| 2212-67-1 | molinate (ISO); S-ethyl 1- perhydroazepinecarbothioate; S-ethyl perhydroazepine-1-carbothioate |
| 2223-95-2 | nickel(II) stearate; nickel(II) octadecanoate |
| 2385-85-5 | dodecachloropentacyclo[5.2.1.02,6.03,9. 05,8]decane; mirex |
| 2437-29-8 | malachite green oxalate |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 2439-01-2 | quinomethionate; chinomethionat (ISO); 6-methyl-1,3-dithiolo(4,5- b)quinoxalin-2-one |
| 2602-46-2 | tetrasodium 3,3'-[[1,1'-biphenyl]-4,4'- diylbis(azo)]bis[5-amino-4- hydroxynaphthalene-2,7-disulphonate];  C.I. Direct Blue 6 |
| 2687-91-4 | N-ethyl-2-pyrrolidone; 1- ethylpyrrolidin-2-one |
| 2795-39-3 | potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1- sulfonate |
| 3033-77-0 | 2,3-epoxypropyltrimethylammonium chloride ...%; glycidyl trimethylammonium chloride ...% |
| 3194-55-6 | 1,2,5,6,9,10-hexabromocyclododecane |
| 3333-67-3 | nickel carbonate; basic nickel carbonate; carbonic acid, nickel (2+) salt |
| 3349-06-2 | nickel diformate |
| 3349-08-4 | nickel(II) propionate |
| 3691-35-8 | chlorophacinone (ISO); 2-(2-(4- chlorophenyl)phenylacetyl)indan-1,3- dione |
| 3724-43-4 | chloro-N,N-dimethylformiminium chloride |
| 3734-48-3 | 4,7-Methanoindene, 4,5,6,7,8,8- hexachloro-delta(sup 1,5)-tetrahydro- |
| 3825-26-1 | ammoniumpentadeca- fluorooctanoate |
| 3861-47-0 | ioxynil octanoate (ISO); 4-cyano-2,6- diiodophenyl octanoate |
| 3906-55-6 | nickel bis(4-cyclohexylbutyrate) |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 4149-60-4 | perfluorononan-1-oic acid, ammonium salts |
| 4454-16-4 | nickel bis(2-ethylhexanoate) |
| 4759-48-2 | 13-cis-Retinoic acid |
| 4995-91-9 | nickel(II) octanoate |
| 5216-25-1 | α, α,α,4-tetrachlorotoluene; p- chlorobenzotrichloride |
| 5300-03-  8 | Alitretinoin |
| 5406-86-  0 | 2-(4-tert-butylphenyl)ethanol |
| 5536-17-4 | Vidarabine |
| 5543-57-7 | (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)- 2-benzopyrone |
| 5543-58-8 | (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)- 2-benzopyrone |
| 5571-36-8 | cyclic 3-(1,2-ethanediylacetale)-estra- 5(10),9(11)-diene-3,17-dione |
| 5786-21-0 | Clozapine |
| 5836-29-3 | coumatetralyl; 4-hydroxy-3-(1,2,3,4- tetrahydro-1-naphthyl)coumarin |
| 6018-89-9 | nickel acetate tetrahydrate; Acetic acid nickel(II) salt |
| 6080-56-  4 | Lead di(acetate) |
| 6094-40-  2 | piperazine hydrochloride |
| 6807-17-6 | 4,4-isobutylethylidenediphenol |
| 7226-23-5 | tetrahydro-1,3-dimethyl-1H-pyrimidin- 2-one; dimethyl propyleneurea |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 7425-14-1 | 2-ethylhexyl-2-ethylhexanoate |
| 7439-92-1 | Lead |
| 7439-97-6 | mercury |
| 7440-43-9 | cadmium |
| 7440-48-  4 | cobalt |
| 7446-27-7 | trilead bis(orthophosphate) |
| 7487-94-7 | mercury dichloride; mercuric chloride |
| 7580-31-6 | 2-ethylhexanoic acid, nickel salt |
| 7646-79-9 | cobalt dichloride |
| 7647-17-8 | Cesium Chloride |
| 7718-54-9 | nickel dichloride; nickel(II) chloride |
| 7758-97-6 | lead chromate |
| 7775-11-3 | sodium chromate |
| 7778-50-9 | potassium dichromate |
| 7784-40-9 | lead hydrogen arsenate |
| 7786-81-4 | nickel sulfate |
| 7789-09-5 | ammonium dichromate |
| 7790-79-6 | cadmium fluoride |
| 7791-20-0 | Nickel Chloride Hexahydrate |
| 8018-01-7 | mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc  salt |
| 9000-55-  9 | Podophyllum Resin |
| 9015-68-3 | Asparaginase |
| 9041-93-4 | Bleomycin sulfate |
| 10022-68-  1 | Cadmium Nitrate Tetrahydrate |
|  |  |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 10028-18-  9 | nickel difluoride |
| 10043-35-  3 | boric acid |
| 10101-97-  0 | nickel (II)sulfate hexahydrate |
| 10108-64-  2 | cadmium chloride |
| 10124-36-  4 | cadmium sulphate |
| 10124-43-  3 | cobalt sulfate |
| 10141-05-  6 | cobalt dinitrate |
| 10486-00-  7 | perboric acid (HBO(O2)), sodium salt, tetrahydrate |
| 10540-29-  1 | Tamoxifen |
| 10588-01-  9 | sodium dichromate |
| 10592-13-  9 | doxycycline hydrochloride; 2-  Naphthacenecarboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,5,10,12,12a- pentahydroxy- 6-methyl-1,11-dioxo-, monohydrochloride, [4S- (4α,4aα,5α,5aα,6α,12aα)]- |
| 10605-21-  7 | carbendazim (ISO); methyl  benzimidazol-2- ylcarbamate |
| 11056-06-  7 | Bleomycin |
| 11113-50-1 | boric acid |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 11130-48-  6 | Gonadotropin, Chorionic |
| 11132-10-8 | nickel potassium fluoride |
| 12008-41-  2 | disodium octaborate anhydrous; |
| 12054-48-  7 | nickel dihydroxide |
| 12179-04-  3 | disodium tetraborate pentahydrate; borax pentahydrate |
| 12267-73-  1 | tetraboron disodium heptaoxide, hydrate |
| 12280-03-  4 | disodium octaborate anhydrous; |
| 12427-38-  2 | maneb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) |
| 12607-70-  4 | [carbonato(2-)] tetrahydroxytrinickel |
| 12656-85-  8 | lead chromate molybdate sulfate red;  C.I. Pigment Red 104; [This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 77605.] |
| 13138-45-  9 | nickel dinitrate |
| 13311-84-  7 | Flutamide |
| 13424-46-  9 | lead diazide; lead azide |
| 13462-88-  9 | nickel dibromide |
| 13462-90-  3 | nickel diiodide |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 13463-39-  3 | tetracarbonylnickel; nickel tetracarbonyl |
| 13517-20-  9 | perboric acid (H3BO2(O2)), monosodium salt, trihydrate |
| 13595-25-  0 | 4,4'-(1,3-phenylene-bis(1- methylethylidene))bis-phenol |
| 13637-71-  3 | nickel diperchlorate; perchloric acid, nickel(II) salt |
| 13647-35-  3 | Trilostane |
| 13654-40-  5 | nickel(II) palmitate |
| 13689-92-  4 | nickel dithiocyanate |
| 13770-89-  3 | nickel bis(sulfamidate); nickel sulfamate |
| 13840-56-  7 | orthoboric acid, sodium salt |
| 13842-46-  1 | nickel dipotassium bis(sulfate) |
| 14216-75-  2 | nitric acid, nickel salt |
| 14550-87-  9 | nickel dibromate |
| 14708-14-  6 | nickel bis(tetrafluoroborate) |
| 14816-18-  3 | phoxim (ISO); α- (diethoxyphosphinothioylimino) phenylacetonitrile |
| 14998-37-  9 | nickel acetate |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 15060-62-  5 | nickel selenate |
| 15245-44-  0 | lead 2,4,6-trinitro-m-phenylene dioxide; lead 2,4,6-trinitroresorcinoxide; lead styphnate |
| 15375-21-  0 | androsta-1,4,9(11)-triene-3,17-dione |
| 15545-48-  9 | chlorotoluron (ISO); 3-(3-chloro-p- tolyl)-1,1-dimethylurea |
| 15571-58-1 | 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo- 8-oxa-3,5-dithia-4-stannatetradecanoate |
| 15586-38-  6 | nickel dichromate |
| 15699-18-  0 | diammonium nickel bis(sulfate) |
| 15843-02-  4 | formic acid, nickel salt |
| 16039-61-  5 | nickel dilactate |
| 16083-14-  0 | nickel(II) trifluoroacetate |
| 16337-84-  1 | carbonic acid, nickel salt |
| 17570-76-  2 | lead(II) methanesulphonate |
| 17630-75-  0 | 5-chloro-1,3-dihydro-2H-indol-2-one |
| 17804-35-  2 | benomyl (ISO); methyl 1- (butylcarbamoyl)benzimidazol-2- ylcarbamate |
| 18283-82-  4 | citric acid, ammonium nickel salt |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 18721-51-2 | nickel(II) hydrogen citrate |
| 20108-78-  5 | valinamide |
| 20830-81-  3 | Daunomycin |
| 21049-39-  8 | perfluorononan-1-oic acid, sodium salt |
| 22398-80-  7 | indium phosphide |
| 22605-92-  1 | citric acid, nickel salt |
| 23031-32-  5 | Terbutaline sulphate |
| 23085-60-  1 | benzyl 2,4-dibromobutanoate |
| 23541-50-  6 | Daunorubicin HCl |
| 24602-86-  6 | tridemorph (ISO); 2,6-dimethyl-4- tridecylmorpholine |
| 25154-52-  3 | nonylphenol |
| 25155-23-  1 | trixylyl phosphate |
| 25301-02-  4 | 4-(2,4,4-trimethylpentan-2-yl)phenol; formaldehyde; oxirane |
| 25321-14-  6 | dinitrotoluene |
| 25383-07-  7 | (R)-α-phenylethylammonium (-)-(1R, 2S)-(1,2-epoxypropyl)phosphonate monohydrate |
| 25637-99-  4 | Hexabromocyclododecane |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CAS No.** | **Chemical Name** |  | **CAS No.** | **Chemical Name** |
| 25808-74- | lead hexafluorosilicate | 36791-04- | Ribavarin |
| 6 |  | 5 |  |
| 26043-11- | nickel hexafluorosilicate | 37244-98- | perboric acid, sodium salt, tetrahydrate |
| 8 |  | 7 |  |
| 27366-72- | N,N-(dimethylamino)thioacetamide | 37894-46- | etacelasil (ISO); 6-(2-chloroethyl)-6-(2- |
| 9 | hydrochloride | 5 | methoxyethoxy)-2,5,7,10-tetraoxa-6- |
|  |  |  | silaundecane |
| 27637-46- | nickel isooctanoate |
| 3 |  | 39300-45- | dinocap (ISO); (RS)-2,6-dinitro-4- octylphenyl crotonates and (RS)-2,4- dinitro-6-octylphenyl crotonates in which “octyl” is a reaction mass of 1- methylheptyl, 1-ethylhexyl and 1- propylpentyl groups |
|  |  | 3 |
| 27882-56- | bromadiolone (ISO); 3- [3-(4′- |
| 7 | bromobiphenyl- 4-yl)-3-hydroxy-1- |  |
|  | phenylpropyl]-4-hydroxy- 2H-chromen- |  |
|  | 2-one |  |
| 29081-56- | ammonium perfluorooctane sulfonate; |  |
| 9 | ammonium | 39807-15- | oxadiargyl (ISO); 3-[2,4-dichloro-5-(2- |
|  | heptadecafluorooctanesulfonate | 3 | propynyloxy)phenyl]-5-(1,1- |
|  |  |  | dimethylethyl)-1,3,4-oxadiazol-2(3H)- |
|  |  |  | one |
| 29317-63- | nickel(II) isooctanoate |
| 3 |  |  |  |
| 39819-65- | nickel bis(benzenesulfonate) |
|  |  | 3 |  |
| 29457-72- | lithium perfluorooctane sulfonate; |
| 5 | lithium heptadecafluorooctanesulfonate |  |  |
| 41575-94- | Carboplatin |
|  |  | 4 |  |
| 30516-87- | Zidovudine (AZT) |
| 1 |  |  |  |
| 41859-67- | bezafibrate |
|  |  | 0 |  |
| 31717-87- | dodemorph acetate; 4-cyclododecyl-2,6- |
| 0 | dimethylmorpholin-4-ium acetate |  |  |
| 49745-95- | Dobutamine hydrochloride |
|  |  | 1 |  |
| 32536-52- | diphenylether; octabromo derivate |
| 0 |  |  |  |
| 50471-44- | vinclozolin (ISO); N-3,5-dichlorophenyl- |
|  |  | 8 | 5-methyl-5-vinyl-1,3-oxazolidine-2,4- dione |
| 33069-62-  4 | Paclitaxel |
|  |  | 51229-78-  8 | cis-1-(3-chloroallyl)-3,5,7-triaza-1- azoniaadamantane chloride |
| 34031-32-  8 | Auranofin |
|  |  | 51818-56-  5 | neodecanoic acid, nickel salt |
| 34256-82-  1 | acetochlor (ISO); 2-chloro-N-  (ethoxymethyl)-N-(2-ethyl-6- |
|  | methylphenyl)acetamide |  |  |
| 52205-73- | Estramustine phosphate sodium |
|  |  | 9 |  |
|  | | |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 52625-25-  9 | nickel 3,5-bis(tert-butyl)-4- hydroxybenzoate |
| 53123-88-  9 | Rapamycin |
| 53152-21-  9 | [5α,7α(S)]-α-tert-butyl-17- (cyclopropylmethyl)-4,5-epoxy-18,19- dihydro-3-hydroxy-6-methoxy-α- methyl-6,14-ethenomorphinan-7- methanol hydrochloride |
| 54965-24-  1 | (Z)-[2-[4-(1,2-diphenylbut-1- enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-hydroxypropane-1,2,3- tricarboxylate |
| 56073-07-  5 | 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1- naphthyl)-4-hydroxycoumarin; difenacoum |
| 56073-10-  0 | 4-hydroxy-3-(3-(4'-bromo-4- biphenylyl)-1,2,3,4-tetrahydro-1- naphthyl)coumarin; brodifacoum |
| 56124-62-  0 | Valrubicin |
| 56420-45-  2 | Epirubicin |
| 56553-60-  7 | sodium triacetoxyborohydride |
| 56634-95-  8 | bromoxynil heptanoate (ISO); 2,6- dibromo-4-cyanophenyl heptanoate |
| 57044-25-  4 | R-2,3-epoxy-1-propanol |
| 57583-34-  3 | 2-ethylhexyl 10-ethyl-4-[[2-[(2- ethylhexyl)oxy]-2-oxoethyl]thio]-4- methyl-7-oxo-8-oxa-3,5-dithia-4- stannatetradecanoate |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 57583-35-  4 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7- oxo-8-oxa-3,5-dithia-4- stannatetradecanoate |
| 57773-63-  4 | Triptorelin |
| 57966-95-  7 | cymoxanil (ISO); 2-cyano-N- [(ethylamino)carbonyl]-2- (methoxyimino)acetamide |
| 58786-99-  5 | Butorphanol tartrate; TORBUTROL |
| 58957-92-  9 | Idarubicin |
| 60142-96-  3 | Gabapentin |
| 60168-88-  9 | fenarimol (ISO); 2,4'-dichloro-α- (pyrimidin-5-yl)benzhydryl alcohol |
| 61135-33-  9 | 5-Ethynyl-2′-deoxyuridine, (EdU) |
| 61571-06-  0 | tetrahydrothiopyran-3-carboxaldehyde |
| 63612-50-  0 | Nilutamide |
| 65195-55-  3 | avermectin B1a |
| 65277-42-  1 | ketoconazole; 1-[4-[4-[[(2SR,4RS)-2- (2,4-dichlorophenyl)-2-(imidazol-1- ylmethyl)-1,3-dioxolan-4- yl]methoxy]phenyl]piperazin-1- yl]ethanone |
| 65405-96-  1 | [µ-[carbonato(2-)-O:O’]] dihydroxy trinickel |
| 65996-93-  2 | Coal Tar pitch |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 66246-88-  6 | penconazole (ISO); 1-[2-(2,4- dichlorophenyl)pentyl]-1H-1,2,4-triazole |
| 67564-91-  4 | fenpropimorph (ISO); cis-4-[3-(p-tert- butylphenyl)-2-methylpropyl]-2,6- dimethylmorpholine |
| 67952-43-  6 | nickel dichlorate |
| 68047-06-  3 | 4-Hydroxytamoxifen |
| 68049-  83-2 | azafenidin (ISO); 2-(2,4-dichloro-5- prop-2-ynyloxyphenyl)-5,6,7,8- tetrahydro-1,2,4-triazolo[4,3-a]pyridin- 3(2H)-one |
| 68130-19-  8 | silicic acid, lead nickel salt |
| 68134-59-  8 | formic acid, copper nickel salt |
| 68392-35-  8 | (Z)-4-(1-(4-(2-  (dimethylamino)ethoxy)phenyl)-2- phenylbut-1-enyl)phenol |
| 68515-42-  4 | 1,2-benzenedicarboxylic acid; di-C7-11- branched and linear alkylesters |
| 68515-50-  4 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear |
| 68694-11-  1 | triflumizole (ISO); (1E)-N-[4-chloro-2- (trifluoromethyl)phenyl]-1- (1H- imidazol-1-yl)-2- propoxyethanimine |
| 68937-41-  7 | Phenol, isopropylated, phosphate (3:) |
| 69806-  50-4 | fluazifop-butyl (ISO); butyl (RS)-2-[4- (5-trifluoromethyl-2- pyridyloxy)phenoxy]propionate |
| 70225-14-  8 | diethanolamine perfluorooctane sulfonate |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 70476-82-  3 | Mitoxantrone HCl |
| 70657-70-  4 | 2-methoxypropyl acetate |
| 71125-38-  7 | Meloxicam |
| 71720-48-  4 | ethyl hydrogen sulfate, nickel(II) salt |
| 71751-41-2 | abamectin (combination of avermectin B1a and avermectin B1b) (ISO) |
| 71888-89-  6 | 1,2-benzenedicarboxylic acid; di-C6-8- branched alkylesters, C7-rich |
| 71957-07-  8 | bis(.sc.d.sc.-gluconato-O1,O2)nickel |
| 72319-19-  8 | 2,7-naphthalenedisulfonic acid, nickel(II) salt |
| 74381-53-  6 | Leuprolide acetate; leupron |
| 74499-35-  7 | phenol, 2-dodecyl-, branched; phenol, 3- dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives |
| 75113-37-  0 | dibutyltin hydrogen borate |
| 75330-75-  5 | (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-  hydroxy-6-oxooxan-2-yl]ethyl}-3,7- dimethyl-1,2,3,7,8,8a- hexahydronaphthalen-1-yl (2S)-2- methylbutanoate |
| 75980-60-  8 | diphenyl(2,4,6- trimethylbenzoyl)phosphine oxide |
| 76932-56-  4 | Nafarelin |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 77182-82-  2 | glufosinate ammonium (ISO); ammonium 2-amino-4- (hydroxymethylphosphinyl)butyrate |
| 79241-46-  6 | fluazifop-P-butyl (ISO); butyl (R)-2-[4- (5-trifluoromethyl-2- pyridyloxy)phenoxy]propionate |
| 79622-59-  6 | fluazinam (ISO); 3-chloro-N-[3-chloro- 2,6-dinitro-4-(trifluoromethyl)phenyl]- 5-(trifluoromethyl)pyridin-2-amine |
| 79815-20-  6 | (S)-2,3-dihydro-1H-indole-2-carboxylic acid |
| 79902-63-  9 | (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-  Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)- tetrahydro-4-hydroxy-6-oxo-2H-pyran- 2-yl]ethyl]-1-naphthalenyly-2,2- dimethyl butanoate |
| 80387-97-  9 | 2-ethylhexyl[[[3,5-bis(1,1- dimethylethyl)-4- hydroxyphenyl]methyl]thio]acetate |
| 82410-32-  0 | ganciclovir |
| 82413-20-  5 | (E)-3-[1-[4-[2-  (dimethylamino)ethoxy]phenyl]-2- phenylbut-1-enyl]phenol |
| 82560-54-  1 | benfuracarb (ISO); ethyl N-[2,3- dihydro-2,2-dimethylbenzofuran-7- yloxycarbonyl(methyl)aminothio]-N- isopropyl- β-alaninate |
| 82640-  04-8 | Raloxifene HCl |
| 82952-64-  5 | Trimetrexate glucuronate |
| 84245-12-  5 | N-[6,9-dihydro-9-[[2-hydroxy-1- (hydroxymethyl)ethoxy]methyl]-6-oxo- 1H-purin-2-yl]acetamide |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 84371-65-  3 | Mifepristone |
| 84777-06-  0 | 1,2-benzenedicarboxylic acid, dipentylester, branched and linear |
| 84852-15-  3 | 4-nonylphenol, branched |
| 84852-35-  7 | (isooctanoato-O)(neodecanoato- O)nickel |
| 84852-36-  8 | (isodecanoato-O)(isononanoato- O)nickel |
| 84852-37-  9 | nickel bis(isononanoate) |
| 84852-39-  1 | (2-ethylhexanoato-O)(isodecanoato- O)nickel |
| 85135-77-  9 | (2-ethylhexanoato-O)(neodecanoato- O)nickel |
| 85166-19-  4 | (isodecanoato-O)(isooctanoato-O)nickel |
| 85508-43-  6 | nickel(II) isodecanoate |
| 85508-44-  7 | nickel(II) neodecanoate |
| 85508-45-  8 | (2-ethylhexanoato-O)(isononanoato- O)nickel |
| 85508-46-  9 | (isononanoato-O)(isooctanoato-O)nickel |
| 85509-19-  9 | flusilazole (ISO); bis(4- fluorophenyl)(methyl)(1H-1,2,4-triazol- 1-ylmethyl)silane |
| 85551-28-  6 | (isononanoato-O)(neodecanoato- O)nickel |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 85622-93-  1 | Temozolomide |
| 86073-88-  3 | Luteinizing hormone releasing hormone salmon |
| 86386-73-  4 | 1H-1,2,4-Triazole-1-ethanol, .alpha.- (2,4-difluorophenyl)-.alpha.-(1H-1,2,4- triazol-1-ylmethyl)- |
| 87691-88-  1 | 3-(piperazin-1-yl)-benzo[d]isothiazole hydrochloride |
| 88416-50-  6 | Disodium Clodronate Tetrahydrate |
| 88671-89-  0 | myclobutanil (ISO); 2-(4-chlorophenyl)- 2-(1H-1,2,4-triazol-1- ylmethyl)hexanenitrile |
| 90035-  08-8 | Flocoumafen; reaction mass of: cis-4- hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4- trifluoromethylbenzyloxy)phenyl)-1- naphthyl)coumarin; trans-4-hydroxy-3- (1,2,3,4-tetrahydro-3-(4-(4- trifluoromethylbenzyloxy)phenyl)-1- naphthyl)coumarin |
| 90657-55-  9 | trans-4-cyclohexyl-L-proline monohydrochloride |
| 93107-30-  3 | 1-cyclopropyl-6,7-difluoro-1,4-dihydro- 4-oxoquinoline-3-carboxylic acid |
| 93920-09-  3 | nickel(II) neoundecanoate |
| 93920-10-  6 | nickel(II) neononanoate |
| 93983-68-  7 | dimethylhexanoic acid nickel salt |
| 94361-06-  5 | cyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)- 3-cyclopropyl-1-(1H-1,2,4-triazol-1- yl)butan-2-ol |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 94723-86-  1 | 2-butyryl-3-hydroxy-5-thiocyclohexan- 3-yl-cyclohex-2-en-1-one |
| 95058-81-  4 | Gemcitabine |
| 96314-26-  0 | trans-4-phenyl-L-proline |
| 98769-84-  7 | Reboxetine mesylate |
| 99105-77-  8 | sulcotrione (ISO); 2-[2-chloro-4- (methylsulfonyl)benzoyl]cyclohexane- 1,3-dione |
| 99610-72-  7 | 2-(2-hydroxy-3,5-dinitroanilino)ethanol |
| 101205-  02-1 | cycloxydim (ISO); 2-(N- ethoxybutanimidoyl)-3-hydroxy-5- (tetrahydro-2H-thiopyran-3- yl)cyclohex-2-en-1-one |
| 103361-  09-7 | flumioxazin (ISO); N-(7-fluoro-3,4- dihydro-3-oxo-4-prop-2-ynyl-2H-1,4- benzoxazin-6-yl)cyclohex-1-ene-1,2- dicarboxamide |
| 104653-  34-1 | difethialone (ISO); 3-[3-(4′- bromobiphenyl-4-yl)-1,2,3,4- tetrahydronaphthalen-1-yl]- 4-hydroxy- 2H-1-benzothiopyran-2-one |
| 104987-  11-3 | Tacrolimus |
| 105024-  66-6 | (4-ethoxyphenyl)(3-(4-fluoro-3- phenoxyphenyl)propyl)dimethylsilane |
| 107534-  96-3 | tebuconazole (ISO); 1-(4-chlorophenyl)- 4,4-dimethyl-3-(1,2,4-triazol-1- ylmethyl)pentan-3-ol |
| 107868-  30-4 | Exemestane; 6-Methyleneandrosta-1,4- diene-3,17-dione |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 112809-  51-5 | Letrozole |
| 112887-  68-0 | Raltitrexed |
| 113852-  37-2 | Cidofovir |
| 114977-  28-5 | Docetaxel |
| 115662-  06-1 | 5,6,12,13-tetrachloroanthra(2,1,9- def:6,5,10-d'e'f')diisoquinoline- 1,3,8,10(2H,9H)-tetrone |
| 119738-  06-6 | (±) tetrahydrofurfuryl (R)-2-[4-(6- chloroquinoxalin-2- yloxy)phenyloxy]propionate |
| 120511-73-  1 | Anastrozole |
| 121158-  58-5 | phenol, dodecyl-, branched |
| 122111-03-  9 | (+)-2'-Deoxy-2',2'-difluorocytidine hydrochloride |
| 124750-  99-8 | (1-((2'-(2H-tetrazol-5-yl)biphenyl-4- yl)methyl)-2-butyl-4-chloro-1H- imidazol-5-yl)methanol, potassium salt |
| 124904-  93-4 | Ganirelix Acetate |
| 125051-  32-3 | bis(η5-cyclopentadienyl)-bis(2,6- difluoro-3-[pyrrol-1-yl]-phenyl)titanium |
| 125116-  23-6 | metconazole (ISO); (1RS,5RS;1RS,5SR)- 5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H- 1,2,4-triazol-1-ylmethyl)cyclopentanol |
| 125317-  39-7 | Vinorelbine tartrate 1 |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 129453-  61-8 | Fulvestrant |
| 132539-  07-2 | 3-{4-methoxycarbonyl-4-[(1- oxopropyl)phenyl- amino]-1- piperidine}propanoic acid methyl ester hydrochloride |
| 133855-  98-8 | epoxiconazole (ISO); (2RS,3SR)-3-(2- chlorophenyl)-2-(4-fluorophenyl)-[( 1H- 1,2,4-triazol-1-yl)methyl]oxirane |
| 136572-  09-3 | (+)-7-Ethyl-10-[4-(1-piperidino)-1- piperidino]-carbonyloxycamptothecin, monohydrochloride, trihydrate |
| 138164-  12-2 | butroxydim (ISO); 5-(3-butyryl-2,4,6- trimethylphenyl)-2-[1- (ethoxyimino)propyl]-3- hydroxycyclohex-2-en-1-one |
| 139001-  49-3 | profoxydim (ISO); 2-{(EZ)-1-[(2RS)-2-  (4-chlorophenoxy)propoxyimino]butyl}- 3-hydroxy-5-(thian-3-yl)cyclohex-2-en- 1-one |
| 141112-29-  0 | isoxaflutole (ISO); 5-cyclopropyl-1,2- oxazol-4-yl α, α,α-trifluoro-2-mesyl-p- tolyl ketone |
| 141758-  74-9 | (4S)-5-[[2-[[(1S,2R)-1-[[(1S)-2-  [[(1S,2R)-1-[[(1S)-2-[[(1S)-2-[[(1S)-1-  [[(1S)-2-[[(1S)-5-amino-1-[[(1S)-4-  amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-  1-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-1-  [[(1S)-2-[[(1S,2S)-1-[[(1S)-1-[[(1S)-2- [[(1S)-1-[[(1S)-5-amino-1-[[(1 |
| 143322-  57-0 | (R)-5-bromo-3-(1-methyl-2-pyrrolidinyl methyl)-1H-indole |
| 143860-  04-2 | 3-ethyl-2-methyl-2-(3-methylbutyl)-1,3- oxazolidine |
| 144177-  62-8 | (R,S)-2-amino-3,3-dimethylbutane amide |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 145672-  81-7 | Cetrorelix Acetate |
| 148553-  50-8 | (3S)-3-(aminomethyl)-5-methylhexanoic |
| 149591-  38-8 | N,N'-dihexadecyl-N,N'-bis(2- hydroxyethyl)propanediamide |
| 149961-  52-4 | dimoxystrobin (ISO); (E)-2- (methoxyimino)-N-methyl-2-[α-(2,5- xylyloxy)-o-tolyl]acetamide |
| 149979-  41-9 | tepraloxydim (ISO); (RS)-(EZ)-2-{1- [(2E)-3-chloroallyloxyimino]propyl}-3- hydroxy-5-perhydropyran-4-ylcyclohex- 2-en-1-one |
| 151798-  26-4 | 2-[2-hydroxy-3-(2- chlorophenyl)carbamoyl-1- naphthylazo]-7-[2-hydroxy-3-(3- methylphenyl)carbamoyl-1- naphthylazo]fluoren-9-one |
| 154361-  50-9 | Capecitabine |
| 156145-  66-3 | O,O'-(ethenylmethylsilylene)di[(4- methylpentan-2-one)oxime] |
| 159939-  85-2 | 4-[(3-chlorophenyl)(1H-imidazol-1- yl)methyl]-1,2-benzenediamine dihydrochloride |
| 162359-  56-0 | FTY720; 2-amino-2-[2-(4-  octylphenyl)ethyl]-1,3-propanediol, hydrochloride; |
| 163879-  69-4 | reaction mass of: 5-[(4-[(7-amino-1- hydroxy-3-sulfo-2-naphthyl)azo]-2,5- diethoxyphenyl)azo]-2-[(3- phosphonophenyl)azo]benzoic acid; 5- [(4-[(7-amino-1-hydroxy-3-sulfo-2- naphthyl)azo]-2,5-diethoxyphenyl)azo]- 3-[(3-phosphonophenyl)azo]benzoic acid |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 164656-  23-9 | Dutasteride |
| 171228-  49-2 | 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-  difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)- 1-ethyl-2-hydroxypropyl]-1,5-dihydro-5- oxo-4H-1,2,4-triazol-4-yl]phenyl]-1- piperazinyl]phenoxy]methyl]-1-(1H- 1,2,4-triazol-1-yl)-D-threo-pentitol |
| 175865-  59-5 | valganciclovir hydrochloride |
| 175865-  60-8 | Valganciclovir |
| 179324-  69-7 | N,N',N''-((2S,2'S,2''S)-(((1R,1'R,1''R)-  (1,3,5,2,4,6-trioxatriborinane-2,4,6- triyl)tris(3-methylbutane-1,1- diyl))tris(azanediyl))tris(1-oxo-3- phenylpropane-2,1-diyl))tris(pyrazine-2- carboxamide); bortezomib |
| 179463-  17-3 | 1-((4R,5S)-5-((2-aminoethyl)amino)- N2-(10,12-dimethyl-1-oxotetradecyl)-4- hydroxy-L-ornithine)-5-((3R)-3- hydroxy-L-ornithine)-, diacetate (salt); |
| 183196-  57-8 | potassium 1-methyl-3- morpholinocarbonyl-4-[3-(1-methyl-3- morpholinocarbonyl-5-oxo-2-pyrazolin- 4-ylidene)-1-propenyl]pyrazole-5-olate; [containing ≥ 0.5 % N,N- dimethylformamide (EC No 200-679-5)] |
| 198481-  33-3 | 1-(4-[2-(azepan-1-yl)ethoxy]benzyl)-2- (4-hydroxyphenyl)-3-methyl-1H-indol- 5-ol |
| 199327-  61-2 | 7-methoxy-6-(3-morpholin-4-yl- propoxy)-3H-quinazolin-4-one; [containing < 0.5 % formamide |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 203313-  25-1 | spirotetramat (ISO); (5s,8s)-3-(2,5- dimethylphenyl)-8-methoxy-2-oxo-1- azaspiro[4,5]dec-3-en-4-yl ethyl carbonate |
| 210555-  94-5 | phenol, 4-dodecyl-, branched |
| 221354-  37-6 | triammonium 4-[4-[7-(4- carboxylatoanilino)-1-hydroxy-3- sulfonato-2-naphthylazo]-2,5- dimethoxyphenylazo]benzoate |
| 302962-  49-8 | dasatinib |
| 335104-  84-2 | tembotrione (ISO); 2-{2-chloro-4- (methylsulfonyl)-3-[(2,2,2- trifluoroethoxy)methyl]benzoyl}cyclohex ane-1,3-dione |
| 341031-  54-7 | Sunitinib malate |
| 404950-  80-7 | panobinostat |
| 777891-  21-1 | N-[2-(3-acetyl-5-nitrothiophen-2-ylazo)- 5-diethylaminophenyl]acetamide |
| 871700-  17-3 | Trametinib |
| 915087-  33-1 | 4-[3-[4-cyano-3- (trifluoromethyl)phenyl]-5,5-dimethyl- 4-oxo-2-thioxo-1-imidazolidinyl]-2- fluoro-N-methyl- benzamide; 4-[3-[4- cyano-3-(trifluoromethyl)phenyl]-5,5- dimethyl-4-oxo-2-thioxo-1- imidazolidinyl]-2-fluoro-N-methyl- benzamide |
| 936563-  96-1 | 936563-96-1 |

|  |  |
| --- | --- |
| **CAS No.** | **Chemical Name** |
| 1195768-  06-9 | N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2- fluorophenyl}-2,6- difluorobenzenesulfonamide methanesulfonate |

**Appendix C:**

**Biological Agents that Are Potential Reproductive Health Hazards**

|  |  |  |
| --- | --- | --- |
| **Agent Name/Description** | **Disease Name/Description** | **References** |
| *Brucella spp. (B. abortus, B. canis, B. suis, B. melitensis)* | Brucellosis; undulate fever; Bang’s disease; Mediterranean fever; Malta fever | * <https://www.cdc.gov/brucellosis/index.html> * [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/brucella-b-abortus-b-canis-b-melitensis-b-suis-material-safety-data-sheets-msds.html) [health/services/laboratory-biosafety-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/brucella-b-abortus-b-canis-b-melitensis-b-suis-material-safety-data-sheets-msds.html) [biosecurity/pathogen-safety-data-sheets-risk-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/brucella-b-abortus-b-canis-b-melitensis-b-suis-material-safety-data-sheets-msds.html) [assessment/brucella-b-abortus-b-canis-b-melitensis-b-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/brucella-b-abortus-b-canis-b-melitensis-b-suis-material-safety-data-sheets-msds.html) [suis-material-safety-data-sheets-msds.html](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/brucella-b-abortus-b-canis-b-melitensis-b-suis-material-safety-data-sheets-msds.html) |
| *Coccidioides immitis*  and related species | Coccidioidomycosis; Valley Fever | * <http://www.cdc.gov/fungal/diseases/coccidioidomycosis/> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/coccidioides-spp-eng.php) [ftss/coccidioides-spp-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/coccidioides-spp-eng.php) |
| Cytomegalovirus (CMV) | Congenital CMV; infectious mononucleosis; retinitis; glandular fever | * <http://www.cdc.gov/cmv/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/cytomegalovirus-eng.php) [ftss/cytomegalovirus-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/cytomegalovirus-eng.php) |
| Ebola virus | Ebola hemorrhagic fever | * <https://www.cdc.gov/vhf/ebola/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php) [eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/ebola-eng.php) |
| Hepatitis B virus (HBV) | Hepatitis B | * <http://www.cdc.gov/hepatitis/B/index.htm> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepatitis-b-eng.php) [ftss/hepatitis-b-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepatitis-b-eng.php) |
| Hepatitis C virus (HCV) | Hepatitis C | * <http://www.cdc.gov/hepatitis/C/index.htm> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepc-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepc-eng.php) [eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepc-eng.php) |
| Hepatitis E virus (HEV) | Hepatitis E | * <http://www.cdc.gov/hepatitis/HEV/index.htm> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepe-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepe-eng.php) [eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hepe-eng.php) |
| Herpesviruses (various) | Various (herpes simplex;  roseola/Sixth | * <https://www.cdc.gov/std/herpes/default.htm> |

|  |  |  |
| --- | --- | --- |
| **Agent Name/Description** | **Disease Name/Description** | **References** |
|  | disease; infectious mononucleosis; chickenpox/shingles, etc.) | * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/herpes-eng.php) [ftss/herpes-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/herpes-eng.php) |
| Human immunodeficiency virus (HIV) | Acquired immune deficiency syndrome (AIDS) | * <http://www.cdc.gov/hiv/> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hiv-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hiv-vih-eng.php) [vih-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/hiv-vih-eng.php) |
| Influenza virus | Influenza | * <https://www.cdc.gov/flu/index.htm> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/influenza-a-eng.php) [ftss/influenza-a-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/influenza-a-eng.php) |
| *Listeria monocytogenes* | Listeriosis | * <http://www.cdc.gov/listeria/> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/listeria-monocytogenes-eng.php) [ftss/listeria-monocytogenes-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/listeria-monocytogenes-eng.php) |
| Lymphocytic choriomeningitis virus (LCMV; arenavirus) | Encephalitis; meningitis | * <https://www.cdc.gov/listeria/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/lymp-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/lymp-cho-eng.php) [cho-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/lymp-cho-eng.php) |
| Measles virus (morbillivirus) | Measles; rubeola | * <https://www.cdc.gov/measles/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/measles-rougeole-eng.php) [ftss/measles-rougeole-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/measles-rougeole-eng.php) |
| Parvovirus B19 | Fifth disease | * <https://www.cdc.gov/parvovirusb19/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/parvovirus-eng.php) [ftss/parvovirus-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/parvovirus-eng.php) |
| *Plasmodium spp.* | Malaria | * <https://www.cdc.gov/malaria/index.html> * [http://healthycanadians.gc.ca/diseases-conditions-](http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/malaria-paludisme/index-eng.php) [maladies-affections/disease-maladie/malaria-](http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/malaria-paludisme/index-eng.php) [paludisme/index-eng.php](http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/malaria-paludisme/index-eng.php) |
| Rubivirus (togavirus) | Rubella (German measles) | * <https://www.cdc.gov/rubella/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/rub-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/rub-eng.php) [eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/rub-eng.php) |

|  |  |  |
| --- | --- | --- |
| **Agent Name/Description** | **Disease Name/Descrip tion** | **References** |
| *Toxocara spp.* | Toxocariasis; visceral larval migrans (VLM) | * <https://www.cdc.gov/parasites/toxocariasis/> * [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/toxocara-canis-toxocara-cati.html) [health/services/laboratory-biosafety-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/toxocara-canis-toxocara-cati.html) [biosecurity/pathogen-safety-data-sheets-risk-](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/toxocara-canis-toxocara-cati.html) [assessment/toxocara-canis-toxocara-cati.html](https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/toxocara-canis-toxocara-cati.html) |
| *Toxoplasma gondii* | Toxoplasmosis | * <https://www.cdc.gov/parasites/toxoplasmosis/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/msds153e-eng.php) [ftss/msds153e-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/msds153e-eng.php) |
| Varicella zoster virus (VZV; herpesvirus) | Chickenpox/shing les | * <https://www.cdc.gov/chickenpox/index.html> * [http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/var-](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/var-zo-eng.php) [zo-eng.php](http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/var-zo-eng.php) |
| Zika virus (flavivirus) | Microencephaly  ; Zika fever; Guillain- Barré syndrome | * <http://www.cdc.gov/zika> * [http://www.healthycanadians.gc.ca/diseases-conditions-](http://www.healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/index-eng.php) [maladies-affections/disease-maladie/zika-virus/index-](http://www.healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/index-eng.php) [eng.php](http://www.healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/zika-virus/index-eng.php) |

|  |
| --- |
| **Bacteria** |
| Borrelia burgdorferi (Lyme disease) |
| Campylobacter sp. |
| Chlamydia psitaci (psittacosis) |
| Chlamydia trachomatis |
| Clostridium perfringens |
| Listeria monocytogenes |
| Mycobacterium tuberculosis |
| Mycobacterium leprae |
| Neisseria gonorrhoeae |
| Pasteurella multocida |
| Borrelia sp. (relapsing fever) |
| Salmonella sp. |
| Treponema pallidum |
| **Fungi** |
| Blastomyces dermatitidis (blastomycosis) |